Precision Medicine In Psychiatry: Astellas Joins Search For Biomarkers, Drug Targets
Executive Summary
Biomarkers for psychiatric disorders are lacking, but Astellas is investing in its own and external efforts to identify drug targets as well as patients who'll respond to new therapies.
You may also be interested in...
Precision Medicine: Despite Gains, Optimum Use Far From Reached
Progress has been made in areas such as lung and breast cancer, but panelists at a recent conference noted there are many efficiencies yet to be realized in drug development and reimbursement.
Out Of The Wilderness: A Second Chance For Neuropsychiatric R&D?
The reorientation of Big Pharma neuroscience R&D toward a biology-driven approach is creating new hope for the treatment of psychiatric disorders.
Lieber Institute Fills Gap In Neuropsychiatric Research Ecosystem, Seeks Pharma Partnerships
At a time of resurgent interest in CNS, The Lieber Institute for Brain Development’s capabilities and tissue resources set it apart from other brain research initiatives. The privately backed research lab is focused on translating genetic clues to the cause and course of schizophrenia and related disorders into new treatments.